Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Defects in the T cell receptor signalling pathway

Published byBathsheba Washington Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Defects in the T cell receptor signalling pathway"— Presentation transcript:

1 Figure 3 Defects in the T cell receptor signalling pathway
Figure 3 | Defects in the T cell receptor signalling pathway. Constitutive activation of phosphatidylinositol 4,5-bisphosphate 3-kinase δ (PI3Kδ) by gain-of-function mutations leads to an increase in RACα serine/threonine-protein kinase (AKT) phosphorylation and ribosomal protein S6 kinase β1 (S6K1) signalling. Loss of the PI3K inhibitor PTEN likewise leads to increased PI3Kδ activity, causing lymphoproliferation, autoimmunity and antibody deficiency. mTOR, mechanistic target of rapamycin; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; TCR, T cell receptor. Schmidt, R. E. et al. (2017) Autoimmunity and primary immunodeficiency: two sides of the same coin? Nat. Rev. Rheumatol. doi: /nrrheum

Download ppt "Figure 3 Defects in the T cell receptor signalling pathway"

Similar presentations

Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the.

A: inhibition of the erbB2 receptor abolished the protective effects of NRG1 on cTnI and cTnT in NRVM. NRVM were treated with Dox-NRG1 (20 ng/ml) in the.
by Rogelio Zamilpa, and Merry L. Lindsey

by Rogelio Zamilpa, and Merry L. Lindsey
SIGNAL TRANSDUCTION Signal Transduction Pathway Protein Modification Phosphorylation Cascade Protein Kinases.

SIGNAL TRANSDUCTION Signal Transduction Pathway Protein Modification Phosphorylation Cascade Protein Kinases.
Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.
Figure 3 Metabolism in homeostatic chondrocytes

Figure 3 Metabolism in homeostatic chondrocytes
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 Simplified T cell and antigen presenting

Figure 4 Simplified T cell and antigen presenting
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
Figure 1 Current treatments for PNETs

Figure 1 Current treatments for PNETs
IRS-1: Auditing the effectiveness of mTOR inhibitors

IRS-1: Auditing the effectiveness of mTOR inhibitors
Figure 5 Defects in the JAK–STAT signalling pathway

Figure 5 Defects in the JAK–STAT signalling pathway
Leptin and insulin signalling pathways in the Arc.

Leptin and insulin signalling pathways in the Arc.
Figure 1 mTOR pathway activation

Figure 1 mTOR pathway activation
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 4 Possible combination therapies CDK4/6 inhibitors
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 7 Defects in apoptosis

Figure 7 Defects in apoptosis
The Akt-mTOR tango and its relevance to cancer

The Akt-mTOR tango and its relevance to cancer

Similar presentations

Ads by Google